计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L126224-1mg |
1mg |
现货 ![]() |
| |
| L126224-5mg |
5mg |
现货 ![]() |
| |
| L126224-10mg |
10mg |
现货 ![]() |
| |
| L126224-50mg |
50mg |
现货 ![]() |
| |
| L126224-100mg |
100mg |
现货 ![]() |
|
| 别名 | 顺式-3-[8-氨基-1-(2-苯基-7-喹啉基)咪唑并[1,5-A]吡嗪-3-基]-1-甲基环丁醇 | 林西替尼 |
|---|---|
| 英文别名 | Linsitinib (USAN/INN) | Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol | HMS3295G15 | Kinome_3532 | CHEBI:91402 | (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol | S |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | OSI-906 (Linsitinib) |
| 生化机理 | Linsitinib 是一种强效、口服有效和高选择性的双重 ATP 竞争性酪氨酸激酶抑制剂,可抑制胰岛素样生长因子-1 受体(IGF-1R)(IC50:35 nM)和胰岛素受体(IR)(IC50:75 nM)。对(xa0Abl)、ALK、BTK、表皮生长因子受体、表皮生长因子受体 1/2 和 PKA 均无活性。在 1 μM 时对 88 种激酶的抑制率<50%。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 胰岛素样生长因子 I 受体抑制剂 胰岛素受体抑制剂 胰岛素受体相关受体抑制剂 |
| 备注 | 有关更多信息,请参阅SDS。有关溶解度,用法和处理的更多建议?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Linsitinib is a potent, selective insulin-like growth factor-1 receptor (IGF-1R, IC50 = 35 nM) and insulin receptor (IR, IC50 = 75 nM) kinase inhibitor which works to block the autophosphorylation of IGF-1R and IR. Additionally, in vitro studies of Linsitinib have demonstrated its ability to inhibit the proliferation of multiple tumor cell lines.Linsitinib is a selective inhibitor of IGF-1R with IC50 of 35 nM, and modestly potent to InsR with IC50 of 75 nM, and has no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc.
|
| 纯度 | ≥99% |
| PubChem SID | 504766617 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol |
| INCHI | InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28) |
| InChi Key | PKCDDUHJAFVJJB-UHFFFAOYSA-N |
| Smiles | CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O |
| Isomeric SMILES | CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O |
| 分子量 | 421.51 |
| Reaxy-Rn | 25747541 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=25747541&ln= |
| 溶解性 | DMSO 84 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 分子量 | 421.500 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 421.19 Da |
| 单同位素质量Monoisotopic Mass | 421.19 Da |
| 拓扑极表面积Topological Polar Surface Area | 89.300 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 663.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y et al.. (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.. Future Med Chem, 1 (6): (1153-71). [PMID:21425998] |